Yonghyun Lee

Prof. Dr. Yonghyun Lee

Department of Pharmacy, College of Pharmacy, Ewha Womans University, Seoul, Korea
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2019 in Nature Materials
Verified
Journal Article
Closed access
PDF file
Yonghyun LeeYonghyun Lee
Yonghyun Lee
KSKohei Sugihara
Kohei Sugihara
MGMerritt G. Gillilland
Merritt G. Gillilland
SJSangyong Jon
Sangyong Jon
NKNobuhiko Kamada
Nobuhiko Kamada
JMJames Moon
James Moon

26 October 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Yonghyun LeeYonghyun Lee
Yonghyun Lee
NKNobuhiko Kamada
Nobuhiko Kamada
JMJames Moon
James Moon

9 May 2022 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
JSJongyoon Shinn
Jongyoon Shinn
NKNuri Kwon
Nuri Kwon
SLSeon Ah Lee
Seon Ah Lee
Yonghyun LeeYonghyun Lee
Yonghyun Lee

30 January 2024 in ACS Nano
Verified
Journal Article
Closed access
JSJongyoon Shinn
Jongyoon Shinn
SPSeojeong Park
Seojeong Park
SLSeonju Lee
Seonju Lee
NPNayoon Park
Nayoon Park
SKSeojeong Kim
Seojeong Kim
Yonghyun LeeYonghyun Lee
Yonghyun Lee

8 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
Yonghyun LeeYonghyun Lee
Yonghyun Lee
JSJongyoon Shinn
Jongyoon Shinn
CXCheng Xu
Cheng Xu
HDHannah E. Dobson
Hannah E. Dobson
NNNouri Neamati
Nouri Neamati
JMJames Moon
James Moon
Despite significant advances in immune checkpoint blockade (ICB), immunosuppression mediated by tumor-associated myeloid cells (TAMCs) poses a major barrier to cancer immunotherapy. In addition, while immunogenic cell death (ICD) provides a viable approach to inducing anti-tumor immune response, it remains unknown how to effectively trigger ICD while addressing immunosuppressive TAMCs. Here, we show that SC144, a gp130 inhibitor that blocks the IL-6/gp130/STAT3 pathway, induces ICD of tumor cells and polarizes macrophages to M1-phenotype in vitro. However, as SC144 also induces killing of CD8+ T-cells, we sought to deliver SC144 selectively to tumor cells and TAMCs. Toward this goal, we have developed hyaluronic acid-bilirubin nanoparticles (HABN) that accumulate in CD44hi tumor cells and TAMCs. Systemic administration of SC144 loaded in HABN (SC144@HABN) induces apoptosis and ICD of tumor cells, increases the ratio of M1-like to M2-like macrophages, and decreases the frequency of myeloid-derived suppressor cells and CD4+ regulatory T-cells, while promoting anti-tumor CD8+ T-cells. Moreover, SC144@HABN combined with anti-PD-L1 ICB efficiently eliminates MC38 tumors and ICB-resistant 4T1 tumors. Overall, our work demonstrates a therapeutic strategy based on coordinated ICD induction and TAMC modulation and highlights the potential of combination chemoimmunotherapy.

4 February 2021 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
JSJongyoon Shinn
Jongyoon Shinn
SLSunyoung Lee
Sunyoung Lee
HLHyon Kyong Lee
Hyon Kyong Lee
JAJaeeun Ahn
Jaeeun Ahn
SLSeon Ah Lee
Seon Ah Lee
Yonghyun LeeYonghyun Lee
Yonghyun Lee